methotrexate + doxorubicin + vincristine + cyclophosphamide + bleomycin + cisplatin

MVP-CAB is a multi-agent combination chemotherapy regimen consisting of methotrexate, doxorubicin (Adriamycin), vincristine, cyclophosphamide, bleomycin, and cisplatin. It has been primarily investigated as an adjuvant treatment for patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy, particularly in high-risk cases characterized by extravesical extension (pT3/pT4) or regional lymph node involvement (pN1/pN2). The regimen utilizes a diverse set of cytotoxic mechanisms, including DNA alkylation, intercalation, inhibition of folate metabolism, and microtubule disruption, to target residual micrometastatic disease. Clinical retrospective studies have evaluated its efficacy in comparison to other cisplatin-based regimens like MVAC, though it is generally associated with significant toxicity and has largely been superseded by modern standards of care such as gemcitabine-cisplatin.

Other names

MVP-CAB regimen